This study enrolled EGFR-mutated NSCLC patients who had received ≥1 EGFR TKI(s), and 48% of patients experienced tumor regression at doses of 400 mg/day or higher with BLU-945 monotherapy [48]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.